Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Dr. Michael Kauffman

Home/Tag:Dr. Michael Kauffman
13 06, 2010

Thoughts About My Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Dr. Michael Kauffman At ASCO

Tags: , , , , , , , |0 Comments

I started an article about carfilzomib last Tuesday this way:  The Truth About The New Multiple Myeloma Novel Therapy Drug, Carfilzomib:"Is Onyx Pharmaceuticals' new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask."Well, you just read my interview with Dr. Michael Kauffman,

12 06, 2010

Interview With Onyx Pharmaceuticals’ CMO Dr. Michael Kauffman- Part Two

Tags: , , , , , , |0 Comments

Yesterday I explained why my interview with Dr. Kauffman was so informal. Using a relaxed, conversational style allows me to get a feel for the moment. More than that, I can try to get a sense of how my subject really feels. Are the guarded? Or they hiding something? Are he or she genuinely enthusiastic

11 06, 2010

Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Michael Kauffman- Part One

Tags: , , , , , |4 Comments

As promised, here is Part One of my three part series about last Friday's interview with Dr. Michael Kauffman, Chief Medical Officer/for Onyx Pharmaceuticals, maker of the new proteasome inhibitor, carfilzomib.First, here is what Google has to say about Dr. Kauffman:Director, CombinatoRx, Inc. CMO, Onyx PharmaceuticalsBoston , MA Sector: HEALTHCARE / Biotechnology 46 Years Old

8 06, 2010

The Truth About The New Multiple Myeloma Novel Therapy Drug, Carfilzomib

Tags: , , , , |3 Comments

Is Onyx Pharmaceuticals' new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask.The company is pushing comparisons with the only currently available FDA proteasome inhibitor, Velcade. Company officials point to ongoing research study results which show less risk of developing peripheral neuropathy

4 06, 2010

Checking-In From ASCO

Tags: , |0 Comments

Oh my God!  I I don't know how I ever would have managed driving into the city and finding the press room here at McCormick Place if I hadn't grown up in the Chicago area... Traffic is crazy, parking unclear and the facility is massive!   I'm hiding here in the press room and preparing for

3 06, 2010

Multiple Myeloma Research Consortium (MMRC) Announces Data Presentations At ASCO

Tags: , , , |0 Comments

More pre-ASCO news:Multiple Myeloma Research Consortium (MMRC) Announces Data Presentations at 46th Annual American Society of Clinical Oncology (ASCO) Annual MeetingThe Multiple Myeloma Research Consortium (MMRC) today announced the presentation of studies conducted through its clinical sites in collaboration with industry partners, Onyx Pharmaceuticals and Bristol-Myers Squibb, in evaluating promising new therapeutic agents for multiple